Bookmark and Share
BioAssay: AID 1535

Confirmation of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.

Congenital Disorders of Glycosylation (CDG) are autosomal recessive defects in the synthesis of N-linked oligosaccharide chains. CDG group I (CDG-I) defects are defined as those caused by mutations in genes encoding enzymes used for the synthesis and transfer of lipid linked oligosaccharide (LLO) to newly synthesized proteins in the lumen of the ER. The steps in this pathway and the genes more ..
_
   
 Tested Compounds
 Tested Compounds
All(193)
 
 
Active(123)
 
 
Inactive(70)
 
 
 Tested Substances
 Tested Substances
All(202)
 
 
Active(129)
 
 
Inactive(73)
 
 
AID: 1535
Data Source: Burnham Center for Chemical Genomics (BCCG-A141-PMI-Near-Km-Assay-dry powder)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Screening Center Network
BioAssay Version:
Deposit Date: 2009-03-05
Modify Date: 2011-01-05

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 123
Related Experiments
Show more
AIDNameTypeProbeComment
1209HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.Confirmatory depositor-specified cross reference
1220HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphateConfirmatory depositor-specified cross reference
1545Summary - Compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.Summary2 depositor-specified cross reference
1553Screening for Phosphomannose Isomerase inhibitors in cellular based assay using Hela cells.Other depositor-specified cross reference
1574Summary assay for the identification of compounds that inhibit PHOSPHO1Summary1 depositor-specified cross reference
1620Toxicity Screening of PMI Inhibitors in Hela cellsOther depositor-specified cross reference
1020Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary AssayScreening same project related to Summary assay
1217uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary AssaysScreening same project related to Summary assay
1536Confirmation of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate.Confirmatory same project related to Summary assay
1655Counter screen SAR assay for PMM2 inhibitors via a fluorescence intensity assayConfirmatory same project related to Summary assay
1666SAR assay for compounds that inhibit PHOSPHO1Confirmatory same project related to Summary assay
1056SAR analysis of an In Vitro TNAP Dose Response Luminescent AssayConfirmatory same project related to Summary assay
1565uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1Confirmatory same project related to Summary assay
1655Counter screen SAR assay for PMM2 inhibitors via a fluorescence intensity assayConfirmatory same project related to Summary assay
1666SAR assay for compounds that inhibit PHOSPHO1Confirmatory same project related to Summary assay
Description:
Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)
Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)
Network: NIH Molecular Libraries Screening Centers Network (MLSCN)
Grant Number: R03 MH082386-01
Assay Provider: Dr. Hudson H. Freeze, Sanford-Burnham Medical Research Institute, San Diego, CA

Congenital Disorders of Glycosylation (CDG) are autosomal recessive defects in the synthesis of N-linked oligosaccharide chains. CDG group I (CDG-I) defects are defined as those caused by mutations in genes encoding enzymes used for the synthesis and transfer of lipid linked oligosaccharide (LLO) to newly synthesized proteins in the lumen of the ER. The steps in this pathway and the genes encoding them are very similar from yeast to human. It requires 30-40 single gene products, each dependent on the previous step in the linear sequence to produce and transfer the LLO to protein. Therefore, mutations in any step may cause a type of CDG. There is considerable overlap in the clinical presentations between different types of CDG and a broad diversity within each type. The most common form of CDG, called Type Ia (CDG-Ia), is caused by defects in PMM2 (Man-6-P to Man-1-P), the gene that encodes phosphomannomutase. Mortality is 20% in the first 5 yrs, but then patients stabilize. Currently, there is no treatment for the CDG-Ia.

CDG-Ib patients, who are deficient in phosphomannose isomerase (PMI) catalyzing conversion of Man-6-P to Fru-6-P, are successfully treated with free mannose. Unfortunately, mannose therapy is not effective for CDG-Ia patients, most likely due to efficient Man-6-P consumption in the PMI reaction. It is believed that patients with Congenital Disorder of Glycosylation Type Ia (CDG-Ia) will benefit from dietary mannose if there is a simultaneous reduction of phosphomannose isomerase (PMI) activity. This would allow a modest intracellular accumulation of Man-6-P and drive metabolic flux into the glycosylation pathway using the residual PMM2 activity. It is assumed that a non-competitive inhibitor would work best in this setting; however, identification of chemical probes with diverse modes of action (MOA) would be advantageous for further characterization of PMI and PMM variants.

The purpose of this assay is to identify inhibitors of human PMI. This is accomplished by using a G6PD- NADPH-coupled assay. In the assay PMI activity is detected through conversion of its product, fructose-6-phosphate, to glucose-6-phosphate catalyzed by phosphoglucose isomerase (PGI) and subsequent oxidation of glucose-6-phosphate to 6-phosphogluconolactone concomitant with NADP-to-NADPH conversion catalyzed by glucose-6-phosphate dehydrogenase (G6PDH). The NADPH is then detected via a resazurin-diaphorase fluorogenic reaction.

This assay is performed in the presence of near-Km concentrations of the PMI substrate, mannose-6-phosphate, to ensure the identification of inhibitors with diverse MOAs.

This dose response assay is developed and performed to confirm hits originally identified in "HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay" (AID 1209) and to study the structure-activity relationship on analogs of the confirmed hits. Compounds are either acquired from commercial sources or synthesized internally.
Protocol
PMI assay materials:

1) Human PMI protein was provided by Dr. Hudson Freeze (Sanford-Burnham Medical Research Institute, San Diego, CA).
2) Substrate working solution: 50 mM HEPES, pH 7.4, 0.4 mM Mannose-6-phosphate, 1.6 U/ml Diaphorase, 0.2 mM Resazurin.
3) Enzyme working solution: 50 mM HEPES, pH 7.4, 0.44 mM NADP+, 9.048 mM MgCl2, 0.01% Tween 20, 4.6 ug/ml phosphoglucose isomerase, 30 ng/ml PMI, 1.8 ug/ml G6PDH.

PMI Dose-response confirmation protocol:

1) 9 uL of Substrate working solution was added to columns 3-24 of a Greiner 384-well black plate (cat # 784076) using a WellMate bulk dispenser (Matrix)
2) 9 ul of Substrate working solution without mannose-6-p was added to columns 1 and 2 (positive control)
3) Dose-response curves contained 10 concentrations of compounds obtained using 2-fold serial dilution. Compounds were serially diluted in 100% DMSO, and then diluted with water to 10% final DMSO concentration.
4) 2 uL compounds in 10% DMSO were transferred into columns 3-22. Columns 1-2 and 23-24 contained 4 uL of 10% DMSO.
5) 9 uL of Enzyme working solution was added to the whole plate using a Thermo Multidrop Combi dispenser.
6) Plates were incubated at room temperature for 30 min.
7) The plates were read on an Analyst plate reader (Molecular Devices), Ex544, Em590.
8) Data analysis was performed using CBIS software (ChemInnovations, Inc).
Comment
The compounds were tested in 1 or more concentration ranges.

Range1 0-100 uM
Range2 0-1 uM
Range3 0-10 uM
Range4 0-50 uM
Range5 0-5 uM
Range6 0-0.5 uM
For all samples in each range that resolved to an IC50 the results were averaged and reported as IC50_Range. The IC50 results for all of the IC50s were averaged to produce IC50_Mean.

Compounds with an IC50_Mean < 100 uM are considered to be active in this assay.

To simplify the distinction between the inactives of the primary screen and of the confirmatory screening stage, the Tiered Activity Scoring System was developed and implemented. Its utilization for the PMI assay is described below.

Activity Scoring
Activity scoring rules were devised to take into consideration compound efficacy, its potential interference with the assay and the screening stage that the data was obtained. Details of the Scoring System will be published elsewhere. Briefly, the outline of the scoring system utilized for the PMI assay is as follows:

1) First tier (0-40 range) is reserved for primary screening data data and is not applicable to this assay.

2) Second tier (41-80 range) is reserved for dose-response confirmation data and is not applicable to this assay.

3) Third tier (81-100 range) is reserved for resynthesized true positives and their analogues

a. Inactive compounds of the confirmatory stage are assigned a score value equal 81.
b. The score is linearly correlated with a compound's inhibitory potency and, in addition, provides a measure of the likelihood that the compound is not an artifact based on the available information.
c. The Hill coefficient is taken as a measure of compound behavior in the assay via an additional scaling factor QC:
QC = 2.6*[exp(-0.5*nH^2) - exp(-1.5*nH^2)]
This empirical factor prorates the likelihood of target-specific compound effect vs. its non-specific behavior in the assay. This factor is based on expectation that a compound with a single mode of action that achieved equilibrium in the PMI inhibition assay demonstrates the Hill coefficient value of 1. Compounds deviating from that behavior are penalized proportionally to the degree of their deviation.
d. Summary equation that takes into account the items discussed above is
Score = 82 + 3*(pEC50 - 3)*QC,
where pEC50 is a negative log(10) of the EC50 value expressed in mole/L concentration units. This equation results in the Score values above 50 for compounds that demonstrate high potency and predictable behavior. Compounds that are inactive in the assay or whose concentration-dependent behavior are likely to be an artifact of that assay will generally have lower Score values.
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1IC50_Mean_QualifierThis qualifier is to be used with the next TID, IC50_Mean. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that value.String
2IC50_Mean*IC50 value determined using sigmoidal dose response equationFloatμM
3IC50_Qualifier_1_Range1This qualifier is to be used with the next TID, IC50_Range1. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that value.String
4IC50_1_Range1IC50 value determined using sigmoidal dose response equationFloatμM
5Std.Err(IC50)_1_Range1Standard Error of IC50 valueFloatμM
6nH_1_Range1Hill coefficient determined using sigmoidal dose response equationFloat
7IC50_Qualifier_2_Range1This qualifier is to be used with the next TID, IC50_2_Range1. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that value.String
8IC50_2_Range1The second IC50 value for Range1 determined using sigmoidal dose response equationFloatμM
9Std.Err(IC50)_2_Range1Standard Error of the preceeding IC50 valueFloat
10nH_2_Range1Hill coefficient determined using sigmoidal dose response equationFloat
11IC50_Qualifier_3_Range1This qualifier is to be used with the next TID, IC50_3_Range1. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that valueString
12IC50_3_Range1The third IC50 value for Range1 determined using sigmoidal dose response equationFloatμM
13Std.Err(IC50)_3_Range1Standard Error of the preceeding IC50 valueFloat
14nH_3_Range1Hill coefficient determined using sigmoidal dose response equationFloat
15IC50_Qualifier_1_Range2This qualifier is to be used with the next TID, IC50_1_Range2. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that valueString
16IC50_1_Range2The first IC50 value for Range2 determined using sigmoidal dose response equationFloatμM
17Std.Err(IC50)_1_Range2Standard Error of the preceeding IC50 valueFloat
18nH_1_Range2Hill coefficient determined using sigmoidal dose response equationFloat
19IC50_Qualifier_2_Range2This qualifier is to be used with the next TID, IC50_2_Range2. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that valueString
20IC50_2_Range2The second IC50 value for Range2 determined using sigmoidal dose response equationFloatμM
21Std.Err(IC50)_2_Range2Standard Error of the preceeding IC50 valueFloat
22nH_2_Range2Hill coefficient determined using sigmoidal dose response equationFloat
23IC50_Qualifier_3_Range2This qualifier is to be used with the next TID, IC50_3_Range2. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that valueString
24IC50_3_Range2The third IC50 value for Range2 determined using sigmoidal dose response equationFloatμM
25Std.Err(IC50)_3_Range2Standard Error of the preceeding IC50 valueFloat
26nH_3_Range2Hill coefficient determined using sigmoidal dose response equationFloat
27IC50_Qualifier_4_Range2This qualifier is to be used with the next TID, IC50_2_Range2. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that valueString
28IC50_4_Range2The fourth IC50 value for Range2 determined using sigmoidal dose response equationFloatμM
29Std.Err(IC50)_4_Range2Standard Error of the preceeding IC50 valueFloat
30nH_4_Range2Hill coefficient determined using sigmoidal dose response equationFloat
31IC50_Qualifier_1_Range3This qualifier is to be used with the next TID, IC50_1_Range3. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that value.String
32IC50_1_Range3The first IC50 value for Range3 determined using sigmoidal dose response equationFloatμM
33Std.Err(IC50)_1_Range3Standard Error of the preceeding IC50 valueFloat
34nH_1_Range3Hill coefficient determined using sigmoidal dose response equationFloat
35IC50_Qualifier_2_Range3This qualifier is to be used with the next TID, IC50_2_Range3. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that value.String
36IC50_2_Range3The second IC50 value for Range3 determined using sigmoidal dose response equationFloatμM
37Std.Err(IC50)_2_Range3Standard Error of the preceeding IC50 valueFloat
38nH_2_Range3Hill coefficient determined using sigmoidal dose response equationFloat
39IC50_Qualifier_1_Range4This qualifier is to be used with the next TID, IC50_1_Range4. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that valueString
40IC50_1_Range4The first IC50 value for Range4 determined using sigmoidal dose response equationFloatμM
41Std.Err(IC50)_1_Range4Standard Error of the preceeding IC50 valueFloat
42nH_1_Range4Hill coefficient determined using sigmoidal dose response equationFloat
43IC50_Qualifier_1_Range5This qualifier is to be used with the next TID, IC50_1_Range5. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that valueString
44IC50_1_Range5The first IC50 value for Range5 determined using sigmoidal dose response equationFloatμM
45Std.Err(IC50)_1_Range5Standard Error of the preceeding IC50 valueFloat
46nH_1_Range5Hill coefficient determined using sigmoidal dose response equationFloat
47IC50_Qualifier_1_Range6This qualifier is to be used with the next TID, IC50_1_Range5. If the qualifier is "=", the IC50 result equals the value in that column; if the qualifier is ">", the IC50 result is greater than that valueString
48IC50_1_Range6The first IC50 value for Range5 determined using sigmoidal dose response equationFloatμM
49Std.Err(IC50)_1_Range6Standard Error of the preceeding IC50 valueFloat
50nH_1_Range6Hill coefficient determined using sigmoidal dose response equationFloat
51Excluded_Points_first_point_Range1Flags to indicate which of the first dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
52% inhibition at 0.1953125 uM_first_point_Range1 (0.195312μM**)% inhibition at a given concentrationFloat%
53% inhibition at 0.390625 uM_first_point_Range1 (0.390625μM**)% inhibition at a given concentrationFloat%
54% inhibition at 0.78125 uM_first_point_Range1 (0.78125μM**)% inhibition at a given concentrationFloat%
55% inhibition at 1.5625 uM_first_point_Range1 (1.5625μM**)% inhibition at a given concentrationFloat%
56% inhibition at 3.125 uM_first_point_Range1 (3.125μM**)% inhibition at a given concentrationFloat%
57% inhibition at 6.25 uM_first_point_Range1 (6.25μM**)% inhibition at a given concentrationFloat%
58% inhibition at 12.5 uM_first_point_Range1 (12.5μM**)% inhibition at a given concentrationFloat%
59% inhibition at 25 uM_first_point_Range1 (25μM**)% inhibition at a given concentrationFloat%
60% inhibition at 50 uM_first_point_Range1 (50μM**)% inhibition at a given concentrationFloat%
61% inhibition at 100 uM_first_point_Range1 (100μM**)% inhibition at a given concentrationFloat%
62Excluded_Points_second_point_Range1Flags to indicate which of the second dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
63% inhibition at 0.1953125 uM_second_point_Range1 (0.195312μM**)% inhibition at a given concentrationFloat%
64% inhibition at 0.390625 uM_second_point_Range1 (0.390625μM**)% inhibition at a given concentrationFloat%
65% inhibition at 0.78125 uM_second_point_Range1 (0.78125μM**)% inhibition at a given concentrationFloat%
66% inhibition at 1.5625 uM_second_point_Range1 (1.5625μM**)% inhibition at a given concentrationFloat%
67% inhibition at 3.125 uM_second_point_Range1 (3.125μM**)% inhibition at a given concentrationFloat%
68% inhibition at 6.25 uM_second_point_Range1 (6.25μM**)% inhibition at a given concentrationFloat%
69% inhibition at 12.5 uM_second_point_Range1 (12.5μM**)% inhibition at a given concentrationFloat%
70% inhibition at 25 uM_second_point_Range1 (25μM**)% inhibition at a given concentrationFloat%
71% inhibition at 50 uM_second_point_Range1 (50μM**)% inhibition at a given concentrationFloat%
72% inhibition at 100 uM_second_point_Range1 (100μM**)% inhibition at a given concentrationFloat%
73Excluded_Points_third_point_Range1Flags to indicate which of the third dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
74% inhibition at 100 uM_third_point_Range1 (100μM**)% inhibition at a given concentrationFloat%
75% inhibition at 50 uM_third_point_Range1 (50μM**)% inhibition at a given concentrationFloat%
76% inhibition at 25 uM_third_point_Range1 (25μM**)% inhibition at a given concentrationFloat%
77% inhibition at 12.5 uM_third_point_Range1 (12.5μM**)% inhibition at a given concentrationFloat%
78% inhibition at 6.25 uM_third_point_Range1 (6.25μM**)% inhibition at a given concentrationFloat%
79% inhibition at 3.125 uM_third_point_Range1 (3.125μM**)% inhibition at a given concentrationFloat%
80% inhibition at 1.5625 uM_third_point_Range1 (1.5625μM**)% inhibition at a given concentrationFloat%
81% inhibition at 0.78125 uM_third_point_Range1 (0.78125μM**)% inhibition at a given concentrationFloat%
82% inhibition at 0.390625 uM_third_point_Range1 (0.390625μM**)% inhibition at a given concentrationFloat%
83% inhibition at 0.1953125 uM_third_point_Range1 (0.195312μM**)% inhibition at a given concentrationFloat%
84Excluded_Points_fourth_point_Range1Flags to indicate which of the fourth dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
85% inhibition at 100 uM_fourth_point_Range1 (100μM**)% inhibition at a given concentrationFloat%
86% inhibition at 50 uM_fourth_point_Range1 (50μM**)% inhibition at a given concentrationFloat%
87% inhibition at 25 uM_fourth_point_Range1 (25μM**)% inhibition at a given concentrationFloat%
88% inhibition at 12.5 uM_fourth_point_Range1 (12.5μM**)% inhibition at a given concentrationFloat%
89% inhibition at 6.25 uM_fourth_point_Range1 (6.25μM**)% inhibition at a given concentrationFloat%
90% inhibition at 3.125 uM_fourth_point_Range1 (3.125μM**)% inhibition at a given concentrationFloat%
91% inhibition at 1.5625 uM_fourth_point_Range1 (1.5625μM**)% inhibition at a given concentrationFloat%
92% inhibition at 0.78125 uM_fourth_point_Range1 (0.78125μM**)% inhibition at a given concentrationFloat%
93% inhibition at 0.390625 uM_fourth_point_Range1 (0.390625μM**)% inhibition at a given concentrationFloat%
94% inhibition at 0.1953125 uM_fourth_point_Range1 (0.195312μM**)% inhibition at a given concentrationFloat%
95Excluded_Points_fifth_point_Range1Flags to indicate which of the fifth dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
96% inhibition at 100 uM_fifth_point_Range1 (100μM**)% inhibition at a given concentrationFloat%
97% inhibition at 50 uM_fifth_point_Range1 (50μM**)% inhibition at a given concentrationFloat%
98% inhibition at 25 uM_fifth_point_Range1 (25μM**)% inhibition at a given concentrationFloat%
99% inhibition at 12.5 uM_fifth_point_Range1 (12.5μM**)% inhibition at a given concentrationFloat%
100% inhibition at 6.25 uM_fifth_point_Range1 (6.25μM**)% inhibition at a given concentrationFloat%
101% inhibition at 3.125 uM_fifth_point_Range1 (3.125μM**)% inhibition at a given concentrationFloat%
102% inhibition at 1.5625 uM_fifth_point_Range1 (1.5625μM**)% inhibition at a given concentrationFloat%
103% inhibition at 0.78125 uM_fifth_point_Range1 (0.78125μM**)% inhibition at a given concentrationFloat%
104% inhibition at 0.390625 uM_fifth_point_Range1 (0.390625μM**)% inhibition at a given concentrationFloat%
105% inhibition at 0.1953125 uM_fifth_point_Range1 (0.195312μM**)% inhibition at a given concentrationFloat%
106Excluded_Points_sixth_point_Range1Flags to indicate which of the sixth dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
107% inhibition at 100 uM_sixth_point_Range1 (100μM**)Float%
108% inhibition at 50 uM_sixth_point_Range1 (50μM**)Float%
109% inhibition at 25 uM_sixth_point_Range1 (25μM**)Float%
110% inhibition at 12.5 uM_sixth_point_Range1 (12.5μM**)Float%
111% inhibition at 6.25 uM_sixth_point_Range1 (6.25μM**)Float%
112% inhibition at 3.125 uM_sixth_point_Range1 (3.125μM**)Float%
113% inhibition at 1.5625 uM_sixth_point_Range1 (1.5625μM**)Float%
114% inhibition at 0.78125 uM_sixth_point_Range1 (0.78125μM**)Float%
115% inhibition at 0.390625 uM_sixth_point_Range1 (0.390625μM**)Float%
116% inhibition at 0.1953125 uM_sixth_point_Range1 (0.195312μM**)Float%
117Excluded_Points_first_point_Range2Flags to indicate which of the first dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
118% inhibition at 1 uM_first_point_Range2 (0.0195312μM**)% inhibition at a given concentrationFloat%
119% inhibition at 0.5 uM_first_point_Range2 (10μM**)% inhibition at a given concentrationFloat%
120% inhibition at 0.25 uM_first_point_Range2 (5μM**)% inhibition at a given concentrationFloat%
121% inhibition at 0.125 uM_first_point_Range2 (2.5μM**)% inhibition at a given concentrationFloat%
122% inhibition at 0.0625 uM_first_point_Range2 (1.25μM**)% inhibition at a given concentrationFloat%
123% inhibition at 0.03125 uM_first_point_Range2 (0.625μM**)% inhibition at a given concentrationFloat%
124% inhibition at 0.015625 uM_first_point_Range2 (0.3125μM**)% inhibition at a given concentrationFloat%
125% inhibition at 0.0078125 uM_first_point_Range2 (0.15625μM**)% inhibition at a given concentrationFloat%
126% inhibition at 0.00390625 uM_first_point_Range2 (0.078125μM**)% inhibition at a given concentrationFloat%
127% inhibition at 0.001953125 uM_first_point_Range2 (0.0390625μM**)% inhibition at a given concentrationFloat%
128Excluded_Points_second_point_Range2Flags to indicate which of the second dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
129% inhibition at 1 uM_second_point_Range2 (10μM**)% inhibition at a given concentrationFloat%
130% inhibition at 0.5 uM_second_point_Range2 (5μM**)% inhibition at a given concentrationFloat%
131% inhibition at 0.25 uM_second_point_Range2 (2.5μM**)% inhibition at a given concentrationFloat%
132% inhibition at 0.125 uM_second_point_Range2 (1.25μM**)% inhibition at a given concentrationFloat%
133% inhibition at 0.0625 uM_second_point_Range2 (0.625μM**)% inhibition at a given concentrationFloat%
134% inhibition at 0.03125 uM_second_point_Range2 (0.3125μM**)% inhibition at a given concentrationFloat%
135% inhibition at 0.015625 uM_second_point_Range2 (0.15625μM**)% inhibition at a given concentrationFloat%
136% inhibition at 0.0078125 uM_second_point_Range2 (0.0390625μM**)% inhibition at a given concentrationFloat%
137% inhibition at 0.00390625 uM_second_point_Range2 (0.0195312μM**)% inhibition at a given concentrationFloat%
138% inhibition at 0.001953125 uM_second_point_Range2 (0.078125μM**)% inhibition at a given concentrationFloat%
139Excluded_Points_third_point_Range2Flags to indicate which of the third dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
140% inhibition at 1 uM_third_point_Range2 (1μM**)% inhibition at a given concentrationFloat%
141% inhibition at 0.5 uM_third_point_Range2 (0.5μM**)% inhibition at a given concentrationFloat%
142% inhibition at 0.25 uM_third_point_Range2 (0.25μM**)% inhibition at a given concentrationFloat%
143% inhibition at 0.125 uM_third_point_Range2 (0.125μM**)% inhibition at a given concentrationFloat%
144% inhibition at 0.0625 uM_third_point_Range2 (0.0625μM**)% inhibition at a given concentrationFloat%
145% inhibition at 0.03125 uM_third_point_Range2 (0.03125μM**)% inhibition at a given concentrationFloat%
146% inhibition at 0.015625 uM_third_point_Range2 (0.015625μM**)% inhibition at a given concentrationFloat%
147% inhibition at 0.0078125 uM_third_point_Range2 (0.0078125μM**)% inhibition at a given concentrationFloat%
148% inhibition at 0.00390625 uM_third_point_Range2 (0.00390625μM**)% inhibition at a given concentrationFloat%
149% inhibition at 0.001953125 uM_third_point_Range2 (0.00195312μM**)% inhibition at a given concentrationFloat%
150Excluded_Points_fourth_point_Range2Flags to indicate which of the fourth dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
151% inhibition at 1 uM_fourth_point_Range2 (1μM**)% inhibition at a given concentrationFloat%
152% inhibition at 0.5 uM_fourth_point_Range2 (0.5μM**)% inhibition at a given concentrationFloat%
153% inhibition at 0.25 uM_fourth_point_Range2 (0.25μM**)% inhibition at a given concentrationFloat%
154% inhibition at 0.125 uM_fourth_point_Range2 (0.125μM**)% inhibition at a given concentrationFloat%
155% inhibition at 0.0625 uM_fourth_point_Range2 (0.0625μM**)% inhibition at a given concentrationFloat%
156% inhibition at 0.03125 uM_fourth_point_Range2 (0.03125μM**)% inhibition at a given concentrationFloat%
157% inhibition at 0.015625 uM_fourth_point_Range2 (0.015625μM**)% inhibition at a given concentrationFloat%
158% inhibition at 0.0078125 uM_fourth_point_Range2 (0.0078125μM**)% inhibition at a given concentrationFloat%
159% inhibition at 0.00390625 uM_fourth_point_Range2 (0.00390625μM**)% inhibition at a given concentrationFloat%
160% inhibition at 0.001953125 uM_fourth_point_Range2 (0.00195312μM**)% inhibition at a given concentrationFloat%
161Excluded_Points_fifth_point_Range2Flags to indicate which of the fifth dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
162% inhibition at 1 uM_fifth_point_Range2 (1μM**)% inhibition at a given concentrationFloat%
163% inhibition at 0.5 uM_fifth_point_Range2 (0.5μM**)% inhibition at a given concentrationFloat%
164% inhibition at 0.25 uM_fifth_point_Range2 (0.25μM**)% inhibition at a given concentrationFloat%
165% inhibition at 0.125 uM_fifth_point_Range2 (0.125μM**)% inhibition at a given concentrationFloat%
166% inhibition at 0.0625 uM_fifth_point_Range2 (0.0625μM**)% inhibition at a given concentrationFloat%
167% inhibition at 0.03125 uM_fifth_point_Range2 (0.03125μM**)% inhibition at a given concentrationFloat%
168% inhibition at 0.015625 uM_fifth_point_Range2 (0.015625μM**)% inhibition at a given concentrationFloat%
169% inhibition at 0.0078125 uM_fifth_point_Range2 (0.0078125μM**)% inhibition at a given concentrationFloat%
170% inhibition at 0.00390625 uM_fifth_point_Range2 (0.00390625μM**)% inhibition at a given concentrationFloat%
171% inhibition at 0.001953125 uM_fifth_point_Range2 (0.00195312μM**)% inhibition at a given concentrationFloat%
172Excluded_Points_sixth_point_Range2Flags to indicate which of the sixth dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
173% inhibition at 1 uM_sixth_point_Range2 (1μM**)% inhibition at a given concentrationFloat%
174% inhibition at 0.5 uM_sixth_point_Range2 (0.5μM**)% inhibition at a given concentrationFloat%
175% inhibition at 0.25 uM_sixth_point_Range2 (0.25μM**)% inhibition at a given concentrationFloat%
176% inhibition at 0.125 uM_sixth_point_Range2 (0.125μM**)% inhibition at a given concentrationFloat%
177% inhibition at 0.0625 uM_sixth_point_Range2 (0.0625μM**)% inhibition at a given concentrationFloat%
178% inhibition at 0.03125 uM_sixth_point_Range2 (0.3125μM**)% inhibition at a given concentrationFloat%
179% inhibition at 0.015625 uM_sixth_point_Range2 (0.015625μM**)% inhibition at a given concentrationFloat%
180% inhibition at 0.0078125 uM_sixth_point_Range2 (0.0078125μM**)% inhibition at a given concentrationFloat%
181% inhibition at 0.00390625 uM_sixth_point_Range2 (0.00390625μM**)% inhibition at a given concentrationFloat%
182% inhibition at 0.001953125 uM_sixth_point_Range2 (0.00195312μM**)% inhibition at a given concentrationFloat%
183Excluded_Points_seventh_point_Range2Flags to indicate which of the seventh dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
184% inhibition at 1 uM_seventh_point_Range2 (1μM**)% inhibition at a given concentrationFloat%
185% inhibition at 0.5 uM_seventh_point_Range2 (0.5μM**)% inhibition at a given concentrationFloat%
186% inhibition at 0.25 uM_seventh_point_Range2 (0.25μM**)% inhibition at a given concentrationFloat%
187% inhibition at 0.125 uM_seventh_point_Range2 (0.125μM**)% inhibition at a given concentrationFloat%
188% inhibition at 0.0625 uM_seventh_point_Range2 (0.0625μM**)% inhibition at a given concentrationFloat%
189% inhibition at 0.03125 uM_seventh_point_Range2 (0.03125μM**)% inhibition at a given concentrationFloat%
190% inhibition at 0.015625 uM_seventh_point_Range2 (0.015625μM**)% inhibition at a given concentrationFloat%
191% inhibition at 0.0078125 uM_seventh_point_Range2 (0.0078125μM**)% inhibition at a given concentrationFloat%
192% inhibition at 0.00390625 uM_seventh_point_Range2 (0.00390625μM**)% inhibition at a given concentrationFloat%
193% inhibition at 0.001953125 uM_seventh_point_Range2 (0.00195312μM**)% inhibition at a given concentrationFloat%
194Excluded_Points_eighth_point_Range2Flags to indicate which of the eighth dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
195% inhibition at 1 uM_eighth_point_Range2 (1μM**)% inhibition at a given concentrationFloat%
196% inhibition at 0.5 uM_eighth_point_Range2 (0.5μM**)% inhibition at a given concentrationFloat%
197% inhibition at 0.25 uM_eighth_point_Range2 (0.25μM**)% inhibition at a given concentrationFloat%
198% inhibition at 0.125 uM_eighth_point_Range2 (0.125μM**)% inhibition at a given concentrationFloat%
199% inhibition at 0.0625 uM_eighth_point_Range2 (0.625μM**)% inhibition at a given concentrationFloat%
200% inhibition at 0.03125 uM_eighth_point_Range2 (0.03125μM**)% inhibition at a given concentrationFloat%
201% inhibition at 0.015625 uM_eighth_point_Range2 (0.015625μM**)% inhibition at a given concentrationFloat%
202% inhibition at 0.0078125 uM_eighth_point_Range2 (0.0078125μM**)% inhibition at a given concentrationFloat%
203% inhibition at 0.00390625 uM_eighth_point_Range2 (0.00390625μM**)% inhibition at a given concentrationFloat%
204% inhibition at 0.001953125 uM_eighth_point_Range2 (0.00195312μM**)% inhibition at a given concentrationFloat%
205Excluded_Points_first_point_Range3Flags to indicate which of the first dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
206% inhibition at 10 uM_first_point_Range3 (5μM**)% inhibition at a given concentrationFloat%
207% inhibition at 5 uM_first_point_Range3 (2.5μM**)% inhibition at a given concentrationFloat%
208% inhibition at 2.5 uM_first_point_Range3 (1.25μM**)% inhibition at a given concentrationFloat%
209% inhibition at 1.25 uM_first_point_Range3 (0.625μM**)% inhibition at a given concentrationFloat%
210% inhibition at 0.625 uM_first_point_Range3 (0.3125μM**)% inhibition at a given concentrationFloat%
211% inhibition at 0.3125 uM_first_point_Range3 (0.15625μM**)% inhibition at a given concentrationFloat%
212% inhibition at 0.15625 uM_first_point_Range3 (0.00976562μM**)% inhibition at a given concentrationFloat%
213% inhibition at 0.078125 uM_first_point_Range3 (0.078125μM**)% inhibition at a given concentrationFloat%
214% inhibition at 0.0390625 uM_first_point_Range3 (0.0390625μM**)% inhibition at a given concentrationFloat%
215% inhibition at 0.01953125 uM_first_point_Range3 (0.0195312μM**)% inhibition at a given concentrationFloat%
216Excluded_Points_second_point_Range3Flags to indicate which of the second dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
217% inhibition at 10 uM_second_point_Range3 (5μM**)% inhibition at a given concentrationFloat%
218% inhibition at 5 uM_second_point_Range3 (2.5μM**)% inhibition at a given concentrationFloat%
219% inhibition at 2.5 uM_second_point_Range3 (1.25μM**)% inhibition at a given concentrationFloat%
220% inhibition at 1.25 uM_second_point_Range3 (0.625μM**)% inhibition at a given concentrationFloat%
221% inhibition at 0.625 uM_second_point_Range3 (0.3125μM**)% inhibition at a given concentrationFloat%
222% inhibition at 0.3125 uM_second_point_Range3 (0.15625μM**)% inhibition at a given concentrationFloat%
223% inhibition at 0.15625 uM_second_point_Range3 (0.078125μM**)% inhibition at a given concentrationFloat%
224% inhibition at 0.078125 uM_second_point_Range3 (0.0390625μM**)% inhibition at a given concentrationFloat%
225% inhibition at 0.0390625 uM_second_point_Range3 (0.0195312μM**)% inhibition at a given concentrationFloat%
226% inhibition at 0.01953125 uM_second_point_Range3 (0.00976562μM**)% inhibition at a given concentrationFloat%
227Excluded_Points_third_point_Range3Flags to indicate which of the third dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
228% inhibition at 10 uM_third_point_Range3 (10μM**)% inhibition at a given concentrationFloat%
229% inhibition at 5 uM_third_point_Range3 (5μM**)% inhibition at a given concentrationFloat%
230% inhibition at 2.5 uM_third_point_Range3 (2.5μM**)% inhibition at a given concentrationFloat%
231% inhibition at 1.25 uM_third_point_Range3 (1.25μM**)% inhibition at a given concentrationFloat%
232% inhibition at 0.625 uM_third_point_Range3 (0.625μM**)% inhibition at a given concentrationFloat%
233% inhibition at 0.3125 uM_third_point_Range3 (0.3125μM**)% inhibition at a given concentrationFloat%
234% inhibition at 0.15625 uM_third_point_Range3 (0.15625μM**)% inhibition at a given concentrationFloat%
235% inhibition at 0.078125 uM_third_point_Range3 (0.078125μM**)% inhibition at a given concentrationFloat%
236% inhibition at 0.0390625 uM_third_point_Range3 (0.0390625μM**)% inhibition at a given concentrationFloat%
237% inhibition at 0.01953125 uM_third_point_Range3 (0.0195312μM**)% inhibition at a given concentrationFloat%
238Excluded_Points_fourth_point_Range3Flags to indicate which of the fourth dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
239% inhibition at 10 uM_fourth_point_Range3 (10μM**)% inhibition at a given concentrationFloat%
240% inhibition at 5 uM_fourth_point_Range3 (5μM**)% inhibition at a given concentrationFloat%
241% inhibition at 2.5 uM_fourth_point_Range3 (2.5μM**)% inhibition at a given concentrationFloat%
242% inhibition at 1.25 uM_fourth_point_Range3 (1.25μM**)% inhibition at a given concentrationFloat%
243% inhibition at 0.625 uM_fourth_point_Range3 (0.625μM**)% inhibition at a given concentrationFloat%
244% inhibition at 0.3125 uM_fourth_point_Range3 (0.3125μM**)% inhibition at a given concentrationFloat%
245% inhibition at 0.15625 uM_fourth_point_Range3 (0.15625μM**)% inhibition at a given concentrationFloat%
246% inhibition at 0.078125 uM_fourth_point_Range3 (0.078125μM**)% inhibition at a given concentrationFloat%
247% inhibition at 0.0390625 uM_fourth_point_Range3 (0.0390625μM**)% inhibition at a given concentrationFloat%
248% inhibition at 0.01953125 uM_fourth_point_Range3 (0.0195312μM**)% inhibition at a given concentrationFloat%
249Excluded_Points_first_point_Range4Flags to indicate which of the first dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
250% inhibition at 50 uM_first_point_Range4 (50μM**)% inhibition at a given concentrationFloat%
251% inhibition at 25 uM_first_point_Range4 (25μM**)% inhibition at a given concentrationFloat%
252% inhibition at 12.5 uM_first_point_Range4 (12.5μM**)% inhibition at a given concentrationFloat%
253% inhibition at 6.25 uM_first_point_Range4 (6.25μM**)% inhibition at a given concentrationFloat%
254% inhibition at 3.125 uM_first_point_Range4 (3.125μM**)% inhibition at a given concentrationFloat%
255% inhibition at 1.5625 uM_first_point_Range4 (1.5625μM**)% inhibition at a given concentrationFloat%
256% inhibition at 0.78125 uM_first_point_Range4 (0.78125μM**)% inhibition at a given concentrationFloat%
257% inhibition at 0.390625 uM_first_point_Range4 (0.390625μM**)% inhibition at a given concentrationFloat%
258% inhibition at 0.1953125 uM_first_point_Range4 (0.0195312μM**)% inhibition at a given concentrationFloat%
259% inhibition at 0.09765625 uM_first_point_Range4 (0.0976562μM**)% inhibition at a given concentrationFloat%
260Excluded_Points_second_point_Range4Flags to indicate which of the second dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
261% inhibition at 50 uM_second_point_Range4 (50μM**)% inhibition at a given concentrationFloat%
262% inhibition at 25 uM_second_point_Range4 (25μM**)% inhibition at a given concentrationFloat%
263% inhibition at 12.5 uM_second_point_Range4 (12.5μM**)% inhibition at a given concentrationFloat%
264% inhibition at 6.25 uM_second_point_Range4 (6.25μM**)% inhibition at a given concentrationFloat%
265% inhibition at 3.125 uM_second_point_Range4 (3.125μM**)% inhibition at a given concentrationFloat%
266% inhibition at 1.5625 uM_second_point_Range4 (1.5625μM**)% inhibition at a given concentrationFloat%
267% inhibition at 0.78125 uM_second_point_Range4 (0.78125μM**)% inhibition at a given concentrationFloat%
268% inhibition at 0.390625 uM_second_point_Range4 (0.390625μM**)% inhibition at a given concentrationFloat%
269% inhibition at 0.1953125 uM_second_point_Range4 (0.195312μM**)% inhibition at a given concentrationFloat%
270% inhibition at 0.09765625 uM_second_point_Range4 (0.0976562μM**)% inhibition at a given concentrationFloat%
271Excluded_Points_first_point_Range5Flags to indicate which of the first dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
272% inhibition at 5 uM_first_point_Range5 (5μM**)% inhibition at a given concentrationFloat%
273% inhibition at 2.5 uM_first_point_Range5 (2.5μM**)% inhibition at a given concentrationFloat%
274% inhibition at 1.25 uM_first_point_Range5 (1.25μM**)% inhibition at a given concentrationFloat%
275% inhibition at 0.625 uM_first_point_Range5 (0.625μM**)% inhibition at a given concentrationFloat%
276% inhibition at 0.3125 uM_first_point_Range5 (0.3215μM**)% inhibition at a given concentrationFloat%
277% inhibition at 0.15625 uM_first_point_Range5 (0.15625μM**)% inhibition at a given concentrationFloat%
278% inhibition at 0.078125 uM_first_point_Range5 (0.078125μM**)% inhibition at a given concentrationFloat%
279% inhibition at 0.0390625 uM_first_point_Range5 (0.0390625μM**)% inhibition at a given concentrationFloat%
280% inhibition at 0.01953125 uM_first_point_Range5 (0.0195312μM**)% inhibition at a given concentrationFloat%
281% inhibition at 0.009765625 uM_first_point_Range5 (0.00976562μM**)% inhibition at a given concentrationFloat%
282Excluded_Points_second_point_Range5Flags to indicate which of the second dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
283% inhibition at 5 uM_second_point_Range5 (5μM**)% inhibition at a given concentrationFloat%
284% inhibition at 2.5 uM_second_point_Range5 (2.5μM**)% inhibition at a given concentrationFloat%
285% inhibition at 1.25 uM_second_point_Range5 (1.25μM**)% inhibition at a given concentrationFloat%
286% inhibition at 0.625 uM_second_point_Range5 (0.625μM**)% inhibition at a given concentrationFloat%
287% inhibition at 0.3125 uM_second_point_Range5 (0.3125μM**)% inhibition at a given concentrationFloat%
288% inhibition at 0.15625 uM_second_point_Range5 (0.15625μM**)% inhibition at a given concentrationFloat%
289% inhibition at 0.078125 uM_second_point_Range5 (0.078125μM**)% inhibition at a given concentrationFloat%
290% inhibition at 0.0390625 uM_second_point_Range5 (0.0390625μM**)% inhibition at a given concentrationFloat%
291% inhibition at 0.01953125 uM_second_point_Range5 (0.0195312μM**)% inhibition at a given concentrationFloat%
292% inhibition at 0.009765625 uM_second_point_Range5 (0.00976562μM**)% inhibition at a given concentrationFloat%
293Excluded_Points_first_point_Range6Flags to indicate which of the first dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
294% inhibition at 0.5 uM_first_point_Range6 (0.5μM**)% inhibition at a given concentrationFloat%
295% inhibition at 0.25 uM_first_point_Range6 (0.25μM**)% inhibition at a given concentrationFloat%
296% inhibition at 0.125 uM_first_point_Range6 (0.125μM**)% inhibition at a given concentrationFloat%
297% inhibition at 0.0625 uM_first_point_Range6 (0.0625μM**)% inhibition at a given concentrationFloat%
298% inhibition at 0.03125 uM_first_point_Range6 (0.03125μM**)% inhibition at a given concentrationFloat%
299% inhibition at 0.015625 uM_first_point_Range6 (0.015625μM**)% inhibition at a given concentrationFloat%
300% inhibition at 0.0078125 uM_first_point_Range6 (0.0078125μM**)% inhibition at a given concentrationFloat%
301% inhibition at 0.00390625 uM_first_point_Range6 (0.00390625μM**)% inhibition at a given concentrationFloat%
302% inhibition at 0.001953125 uM_first_point_Range6 (0.00195312μM**)% inhibition at a given concentrationFloat%
303% inhibition at 0.0009765625 uM_first_point_Range6 (0.000976562μM**)% inhibition at a given concentrationFloat%
304Excluded_Points_second_point_Range6Flags to indicate which of the second dose-response points were excluded from analysis. (1) means the titration point was (1) excluded and (0) means the point was not excluded, for the titration series going from low to high compound concentrations.String
305% inhibition at 0.5 uM_second_point_Range6 (0.5μM**)% inhibition at a given concentrationFloat%
306% inhibition at 0.25 uM_second_point_Range6 (0.25μM**)% inhibition at a given concentrationFloat%
307% inhibition at 0.125 uM_second_point_Range6 (0.125μM**)% inhibition at a given concentrationFloat%
308% inhibition at 0.0625 uM_second_point_Range6 (0.0625μM**)% inhibition at a given concentrationFloat%
309% inhibition at 0.03125 uM_second_point_Range6 (0.03125μM**)% inhibition at a given concentrationFloat%
310% inhibition at 0.015625 uM_second_point_Range6 (0.015625μM**)% inhibition at a given concentrationFloat%
311% inhibition at 0.0078125 uM_second_point_Range6 (0.0078125μM**)% inhibition at a given concentrationFloat%
312% inhibition at 0.00390625 uM_second_point_Range6 (0.00390625μM**)% inhibition at a given concentrationFloat%
313% inhibition at 0.001953125 uM_second_point_Range6 (0.00195312μM**)% inhibition at a given concentrationFloat%
314% inhibition at 0.0009765625 uM_second_point_Range6 (0.000976562μM**)% inhibition at a given concentrationFloat%

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: R03 MH082386-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
Classification
PageFrom: